Literature DB >> 9287148

Gut epithelial cells as targets for gene therapy of hemophilia.

J N Lozier1, J R Yankaskas, W J Ramsey, L Chen, H Berschneider, R A Morgan.   

Abstract

Gut epithelium is an attractive target for gene therapy of hemophilia due to the large number of rapidly dividing cells that should be readily accessible to a wide range of vectors by a noninvasive route of administration. We have performed in vitro tests to determine the suitability of gut epithelial cells for gene transfer, protein synthesis, and secretion of coagulation factors VIII and IX. The results with retroviral vectors indicate that transduced epithelial cells from human, rat, or porcine small or large intestine can synthesize significant amounts of factor VIII or factor IX and that two-thirds or more of the recombinant protein is secreted in a basolateral direction (i.e., away from the lumen and toward underlying capillaries and lymphatics). Furthermore, we have demonstrated that intestinal epithelial cells are susceptible to efficient gene transfer by lipofection and adenovirus vectors. In the case of factor IX, we have produced a high-titer adenovirus vector capable of transducing gut epithelial cells resulting in synthesis of factor IX. The results of our in vitro studies indicate that gene transfer targeting gut epithelium as a new approach to hemophilia gene therapy is rational and merits in vivo studies in hemophilia animal models.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9287148     DOI: 10.1089/hum.1997.8.12-1481

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  10 in total

1.  Function and immunolocalization of overexpressed human intestinal H+/peptide cotransporter in adenovirus-transduced Caco-2 cells.

Authors:  C P Hsu; E Walter; H P Merkle; B Rothen-Rutishauser; H Wunderli-Allenspach; J M Hilfinger; G L Amidon
Journal:  AAPS PharmSci       Date:  1999

Review 2.  New pathophysiological insights and modern treatment of IBD.

Authors:  Matthias A Engel; Markus F Neurath
Journal:  J Gastroenterol       Date:  2010-03-09       Impact factor: 7.527

Review 3.  In vitro and in vivo models for the study of oral delivery of nanoparticles.

Authors:  Jennifer M Gamboa; Kam W Leong
Journal:  Adv Drug Deliv Rev       Date:  2013-02-13       Impact factor: 15.470

4.  Gene and cell therapy based treatment strategies for inflammatory bowel diseases.

Authors:  Sander van der Marel; Anna Majowicz; Sander van Deventer; Harald Petry; Daniel W Hommes; Valerie Ferreira
Journal:  World J Gastrointest Pathophysiol       Date:  2011-12-15

Review 5.  miRNAs in gastrointestinal diseases: can we effectively deliver RNA-based therapeutics orally?

Authors:  A K M Nawshad Hossian; Gerardo G Mackenzie; George Mattheolabakis
Journal:  Nanomedicine (Lond)       Date:  2019-11-18       Impact factor: 5.307

6.  Efficient directional cloning of recombinant adenovirus vectors using DNA-protein complex.

Authors:  T Okada; W J Ramsey; J Munir; O Wildner; R M Blaese
Journal:  Nucleic Acids Res       Date:  1998-04-15       Impact factor: 16.971

7.  Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure.

Authors:  S Wirtz; P R Galle; M F Neurath
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

8.  Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors.

Authors:  Hiroshi Matsumoto; Takahiro Kimura; Kazunori Haga; Noriyuki Kasahara; Peter Anton; Ian McGowan
Journal:  BMC Gastroenterol       Date:  2010-05-11       Impact factor: 3.067

9.  Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles.

Authors:  Katherine Bowman; Rita Sarkar; Sanj Raut; Kam W Leong
Journal:  J Control Release       Date:  2008-06-27       Impact factor: 9.776

Review 10.  Targeting the gastrointestinal tract with viral vectors: state of the art and possible applications in research and therapy.

Authors:  Roeland Buckinx; Jean-Pierre Timmermans
Journal:  Histochem Cell Biol       Date:  2016-09-24       Impact factor: 2.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.